Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia

References

• Sigler EJ, Randolph JC, Calzada JI, et al. Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(4):1097–1101. doi:10.1007/s00417-012-2150-1
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Finger RP, Kruse K, et al. Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: a 12-Month Prospective Study. Am J Ophthalmol. 2011;151(5):876–886. doi:10.1016/j.ajo.2010.11.019
   Web of Science ®Google Scholar
• Wu L, Evans T, Arévalo JF, et al. Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia. Retina. 2008;28(2):314–319. doi:10.1097/IAE.0b013e31814cf03e
   Web of Science ®Google Scholar
• De Lahitte GD, Cohen SY, Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol. 2004;138(5):892–894. doi:10.1016/j.ajo.2004.06.010
   PubMed Web of Science ®Google Scholar
• Park DW, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology. 1997;104(11):1838–1846. doi:10.1016/S0161-6420(97)30019-0
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons TE, Peto T, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a Phase 1 safety trial. Am J Ophthalmol. 2015;159(4):659–666. doi:10.1016/j.ajo.2014.12.013
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons TE, Jaffe G, et al. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia Type 2. Ophthalmology. 2019;126(4):540–549. doi:10.1016/j.ophtha.2018.09.041
   PubMed Web of Science ®Google Scholar
• Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100(10):1536–1546. doi:10.1016/S0161-6420(93)31447-8
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Gillies MC, Chew EY, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77. doi:10.1016/j.preteyeres.2012.11.002
   PubMed Web of Science ®Google Scholar
• Gantner ML, Eade K, Wallace M, et al. Serine and lipid metabolism in macular disease and peripheral neuropathy. N Engl J Med. 2019;381:1422. doi:10.1056/NEJMoa1815111
   PubMed Web of Science ®Google Scholar
• Zeimer MB, Padge B, Heimes B, et al. Idiopathic macular telangiectasia type 2: distribution of macular pigment and functional investigations. Retina. 2010;30(4):586–595. doi:10.1097/IAE.0b013e3181bd2d38
   Web of Science ®Google Scholar
• Powner MB, Gillies MC, Tretiach M, et al. Perifoveal müller cell depletion in a case of macular telangiectasia type 2. Ophthalmology. 2010;117(12):2407–2416. doi:10.1016/j.ophtha.2010.04.001
   PubMed Web of Science ®Google Scholar
• Powner MB, Gillies MC, Zhu M, et al. Loss of müllers cells and photoreceptors in macular telangiectasia type 2. Ophthalmology. 2013;120(11):2344–2352. doi:10.1016/j.ophtha.2013.04.013
   Web of Science ®Google Scholar
• Zeimer MB, Isabel I. Spital, G et al. Macular telangiectasia patterns of distribution of macular pigment and Response to Supplementation. Retina. 2010;30(8):1282–1293. doi:10.1097/IAE.0b013e3181e096dd
   PubMed Web of Science ®Google Scholar
• Choi RY, Gorusupudi A, Wegner K, et al. Macular pigment distribution responses to high-dose zeaxanthin supplementation in patients with macular telangiectasia type 2. Retina. 2017;37(12):2238–2247. doi:10.1097/IAE.0000000000001450
   Web of Science ®Google Scholar
• Tan ACS, Balaratnasingam C, Yannuzzi LA. Treatment of macular telangiectasia type 2 with carotenoid supplements containing meso-zeaxanthin: a pilot study. Ophthalmic Surg Lasers Imaging Retina. 2016;47(6):528–535. doi:10.3928/23258160-20160601-04
   Web of Science ®Google Scholar
• Yannuzzi LA, Bardal AMC, Freund KB, et al. Idiopathic Macular Telangiectasia. Arch Ophthalmol. 2006;124(4):450–460. doi:10.1001/archopht.124.4.450
   PubMedGoogle Scholar
• Heeren TFC, Chew EY, Clemons T, et al. macular telangiectasia type 2: visual acuity, disease end stage, and the macTel area: macTel project report number 8. Ophthalmology. 2020;127(11):1539–1548. doi:10.1016/j.ophtha.2020.03.040
   PubMed Web of Science ®Google Scholar
• Peto T, Heeren TFC, Clemons TE, et al.Correlation of clinical and structural progression with visual acuity loss in macular telangiectasia type 2. Retina. 2018;(38):8–13. doi:10.1097/IAE.0000000000001697
   Web of Science ®Google Scholar
• Heeren TFC, Kitka D, Florea D, et al.Longitudinal correlation of ellipsoid zone loss and functional loss in macular telangiectasia type 2. Retina. 2018;(38):20–26. doi:10.1097/IAE.0000000000001715
   Web of Science ®Google Scholar
• Pauleikhoff D, Bonelli R, Dubis AM, et al. Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. Acta Ophthalmol. 2019;97:998–1005. doi:10.1111/aos.14110
   Web of Science ®Google Scholar
• Sallo FB, Peto T, Egan C, et al. “En face” OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012;53(10):6145–6152. doi:10.1167/iovs.12-10580
   PubMed Web of Science ®Google Scholar
• Cai CX, Choong J, Farsiu S, et al. Retinal cavitations in macular telangiectasia type 2 (MacTel): longitudinal structure-function correlations. Br J Ophthalmol. 2021;105(1):109–112. doi:10.1136/bjophthalmol-2019-315416
   Web of Science ®Google Scholar
• Lima VC, Rosen RB, Farah M. Macular pigment in retinal health and disease. Int J Retina Vitreous. 2016;2:1. doi:10.1186/s40942-016-0044-9
   Google Scholar
• Whitehead AJ, Mares JA, Danis RP. Macular pigment: a review of current knowledge. Arch Ophthalmol. 2006;124(7):1038–1045. doi:10.1001/archopht.124.7.1038
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. doi:10.1001/archopht.119.10.1417
   PubMed Web of Science ®Google Scholar
• Dorrell MI, Aguilar E, Jacobson R, et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest. 2009;119(3):611–623. doi:10.1172/JCI35977
   Web of Science ®Google Scholar
• Cheng Z, Zhang T, Zheng J, et al. Betulinic acid derivatives can protect human Müller cells from glutamate-induced oxidative stress. Exp Cell Res. 2019;383:1. doi:10.1016/j.yexcr.2019.111509
   Web of Science ®Google Scholar
• Toft-Kehler AK, Gurubaran IS, Desler C, et al. Oxidative stress-induced dysfunction of müller cells during starvation. Invest Ophthalmol Visual Sci. 2016;57(6):2721–2728. doi:10.1167/iovs.16-19275
   PubMed Web of Science ®Google Scholar
• Zhang X, Feng Z, Li C, Zheng Y. Morphological and migratory alterations in retinal müller cells during early stages of hypoxia and oxidative stress. Neural Regen Res. 2012;7(1):31–35. doi:10.3969/j.issn.1673-5374.2012.01.005
   Web of Science ®Google Scholar